Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

The financial cost of preventive and curative programs for breast cancer: a case study of women in Shiraz-Iran.

Hatam N, Keshtkar V, Salehi A, Rafei H.

Int J Health Policy Manag. 2014 May 8;2(4):187-91. doi: 10.15171/ijhpm.2014.44. eCollection 2014 May.

2.

Cost-effectiveness of health-related lifestyle advice delivered by peer or lay advisors: synthesis of evidence from a systematic review.

Pennington M, Visram S, Donaldson C, White M, Lhussier M, Deane K, Forster N, Carr SM.

Cost Eff Resour Alloc. 2013 Dec 4;11(1):30. doi: 10.1186/1478-7547-11-30.

3.

Cost effectiveness of breast cancer screening using mammography; a systematic review.

Rashidian A, Barfar E, Hosseini H, Nosratnejad S, Barooti E.

Iran J Public Health. 2013 Apr 1;42(4):347-57. Print 2013.

4.

Cost effectiveness of the NHS breast screening programme: life table model.

Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N.

BMJ. 2013 May 9;346:f2618. doi: 10.1136/bmj.f2618. Erratum in: BMJ. 2013;346:f3822.

5.

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals.

van Ravesteyn NT, Heijnsdijk EA, Draisma G, de Koning HJ.

Br J Cancer. 2011 Sep 27;105(7):1082-8. doi: 10.1038/bjc.2011.300. Epub 2011 Aug 23.

6.

Calibration methods used in cancer simulation models and suggested reporting guidelines.

Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS.

Pharmacoeconomics. 2009;27(7):533-45. doi: 10.2165/11314830-000000000-00000. Review.

7.

Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.

Ahern CH, Shen Y.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):718-25. doi: 10.1158/1055-9965.EPI-08-0918. Epub 2009 Mar 3.

8.

Impact of UK policy initiatives on use of medicines to aid smoking cessation.

West R, DiMarino ME, Gitchell J, McNeill A.

Tob Control. 2005 Jun;14(3):166-71.

9.

Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy.

Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, Birnie E, Buijs-van der Woude T, Mali WP, de Koning HJ, Buskens E.

Br J Cancer. 2004 Jan 26;90(2):383-92.

10.

Interval cancers in the Dutch breast cancer screening programme.

Fracheboud J, de Koning HJ, Beemsterboer PM, Boer R, Verbeek AL, Hendriks JH, van Ineveld BM, Broeders MJ, de Bruyn AE, van der Maas PJ.

Br J Cancer. 1999 Nov;81(5):912-7.

11.

Universal HIV screening of pregnant women in England: cost effectiveness analysis.

Postma MJ, Beck EJ, Mandalia S, Sherr L, Walters MD, Houweling H, Jager JC.

BMJ. 1999 Jun 19;318(7199):1656-60.

12.

NHS breast screening programme. Both extended age range and reduced screening interval are needed.

Goodare H, King M.

BMJ. 1999 Feb 6;318(7180):397-8. No abstract available.

13.

Extending the benefits of breast cancer screening. Still hard to know how large the benefits will really be.

Werneke U, McPherson K.

BMJ. 1998 Aug 8;317(7155):360-1. No abstract available.

Supplemental Content

Support Center